EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate

Qiu-Yan Zhang, Yang Zhang, Zhe-Rui Zhang, Yue Li, Qi Yan, Ya-Nan Zhang iD, Bo Zhang iD

Journal of Virology · 18.08.2026 · 100 (8)

DOI: 10.1128/jvi.00568-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, erschienen am 18.08.2026. Verfasst von Qiu-Yan Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China. Hauptthemen laut MEDLINE: Newcastle disease virus, Viral Vaccines, Chikungunya virus, Chikungunya Fever. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

With the broad spread of the chikungunya virus (CHIKV), there is an increasing demand for more effective and protective vaccines. In this study, we first developed a Newcastle disease virus (NDV) vector vaccine candidate expressing the complete envelope (E3–E1) protein of CHIKV. The immunoelectron microscopy confirmed the presence of E2 protein in the rNDV-CHIKV virion, and the virological results showed that the expression of E1 and E2 protein was stable after 10 serial passages in embryonated chicken eggs. Moreover, we assessed its safety and immunogenicity following intramuscular (i.m.) or subcutaneous (s.c.) administration in C57BL/6 mice. The immunogenicity analyses demonstrated that a single-dose immunization elicits high titers of CHIKV E2-specific IgG antibodies, potent neutralizing activity, and T-cell immune responses. Importantly, both routes of immunization conferred complete protection against wild-type CHIKV challenge in C57BL/6 mice. These findings present a promising novel vector-based vaccine candidate with significant potential for effective CHIKV prevention. IMPORTANCE Chikungunya virus (CHIKV) imposes a substantial global health burden, characterized by arthralgia that can persist for years, neurological complications, and potentially fatal outcomes in vulnerable populations. Currently, two vaccines against CHIKV have been approved: a live-attenuated vaccine (Ixchiq) and a virus-like particle (VLP) vaccine (Vimkunya). However, Ixchiq has been withdrawn from clinical use due to significant side effects, highlighting the urgent need for the development of novel vaccine strategies. Our research has successfully developed a novel vaccine candidate that utilizes Newcastle disease virus as a vector to express CHIKV antigens. This innovative strategy offers multiple advantages: cost-effectiveness, genetic stability of the inserted gene, and robust immunogenicity with effective immune protection. This approach offers a contribution in addressing the emerging threat posed by CHIKV.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Newcastle disease virusViral VaccinesChikungunya virusChikungunya FeverAnimalsMiceAntibodies, ViralMice, Inbred C57BLAntibodies, NeutralizingViral Envelope ProteinsFemaleImmunoglobulin GGenetic Vectors

Stichwörter der Autor:innen

Newcastle disease viruschikungunya virusvector vaccine

Substanzen

Viral VaccinesAntibodies, ViralAntibodies, NeutralizingViral Envelope ProteinsImmunoglobulin G

Autor:innen und Institutionen

  • State Key Laboratory of Virology and Biosafety, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Department of Good Clinical Practice, Medical Guarantee Center, Second Affiliated Hospital of Naval Medical University, Shanghai, China.
  • Department of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

ORCID-Profile: Ya-Nan Zhang, Bo Zhang

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhang, Q. Y., Zhang, Y., Zhang, Z. R., Li, Y., Yan, Q., Zhang, Y. N., & Zhang, B. (2026). A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate. Journal of Virology, 100(8). https://doi.org/10.1128/jvi.00568-26

Vancouver

Zhang QY, Zhang Y, Zhang ZR, Li Y, Yan Q, Zhang YN, et al. A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate. Journal of Virology. 2026;100(8). doi:10.1128/jvi.00568-26

BibTeX
@article{Zhang2026,
  author = {Zhang, Qiu-Yan and Zhang, Yang and Zhang, Zhe-Rui and Li, Yue and Yan, Qi and Zhang, Ya-Nan and Zhang, Bo},
  title = {A single-dose chimeric Newcastle disease virus (NDV)/chikungunya virus (CHIKV) is an effective CHIKV vaccine candidate},
  journal = {Journal of Virology},
  year = {2026},
  volume = {100},
  number = {8},
  doi = {10.1128/jvi.00568-26}
}
Kostenlos starten →